AR088296A1 - Citramida de rasagilina, proceso de preparación y composicion farmaceutica - Google Patents
Citramida de rasagilina, proceso de preparación y composicion farmaceuticaInfo
- Publication number
- AR088296A1 AR088296A1 ARP120103780A AR088296A1 AR 088296 A1 AR088296 A1 AR 088296A1 AR P120103780 A ARP120103780 A AR P120103780A AR 088296 A1 AR088296 A1 AR 088296A1
- Authority
- AR
- Argentina
- Prior art keywords
- rasagiline
- citramide
- pharmaceutical composition
- mixing
- dimethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Un compuesto aislado, caracterizado porque tiene la estructura de fórmula (1), o una sal del mismo. Reivindicación 3: Un proceso para preparar citramida de rasagilina caracterizado porque comprende los pasos de: a) mezclar ácido cítrico con cloruro de tionilo en un primer solvente bajo una atmósfera inerte a una temperatura menor de 30ºC para obtener citrato de trimetilo; b) mezclar el citrato de trimetilo que se obtuvo del paso a) y una solución de NaOH en un segundo solvente a una temperatura menor de 30ºC para obtener citrato de 1,2-dimetilo; c) mezclar el citrato de 1,2-dimetilo que se obtuvo del paso b) y cloruro de tionilo en un tercer solvente a una temperatura menor de 30ºC para obtener un residuo aceitoso; d) mezclar el residuo aceitoso proveniente del paso c) y una mezcla de rasagilina y trietilamina en el tercer solvente a una temperatura menor de 30ºC para obtener 1-rasagilina-2,3-dimetil citramida; y e) mezclar una solución acuosa de LiOH y 1-rasagilina-2,3-dimetil citramida que se obtuvo del paso d) en una combinación de solventes a una temperatura menor de 30ºC; y f) ajustar el pH de la mezcla de reacción del paso e) con un ácido para obtener 1-citramida de rasagilina. Reivindicación 9: Una composición farmacéutica caracterizada porque comprende rasagilina o una sal farmacéuticamente aceptable de la misma, ácido cítrico, citramida de rasagilina o una sal de la misma, y por lo menos un vehículo farmacéuticamente aceptable, donde la citramida de rasagilina está presente en la composición farmacéutica en una cantidad mayor de aproximadamente 0,03%, en peso, con relación a la cantidad de rasagilina, en base a una determinación realizada por un método de HPLC, y con la salvedad de que, si la composición farmacéutica tiene por lo menos cuatro meses desde su preparación, entonces la temperatura de la composición farmacéutica durante dicho período no haya superado la temperatura ambiente durante un período total de cuatro meses o más.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545414P | 2011-10-10 | 2011-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088296A1 true AR088296A1 (es) | 2014-05-21 |
Family
ID=48042234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103780 AR088296A1 (es) | 2011-10-10 | 2012-10-10 | Citramida de rasagilina, proceso de preparación y composicion farmaceutica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130089611A1 (es) |
| EP (1) | EP2766007A4 (es) |
| JP (1) | JP2014534195A (es) |
| KR (1) | KR20140074388A (es) |
| CN (1) | CN103857389A (es) |
| AR (1) | AR088296A1 (es) |
| AU (1) | AU2012323346A1 (es) |
| BR (1) | BR112014008550A2 (es) |
| CA (1) | CA2851274A1 (es) |
| EA (1) | EA201490756A1 (es) |
| HK (1) | HK1200313A1 (es) |
| IL (1) | IL231720A0 (es) |
| MX (1) | MX2014004196A (es) |
| WO (1) | WO2013055684A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007217349B9 (en) * | 2006-02-21 | 2013-06-27 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Multiple System Atrophy |
| WO2007117431A2 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| ZA200903903B (en) * | 2006-12-14 | 2010-08-25 | Teva Pharma | Crystalline solid rasagiline base |
| AU2009204454B2 (en) * | 2008-01-11 | 2015-02-05 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| EP2285214B1 (en) * | 2008-06-10 | 2012-05-16 | Teva Pharmaceutical Industries Ltd. | Rasagiline soft gelatin capsules |
| US8946482B2 (en) | 2009-07-09 | 2015-02-03 | Ratiopharm Gmbh | Salts of rasagiline and pharmaceutical preparations thereof |
| EP2485722A1 (en) * | 2009-10-09 | 2012-08-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of progressive supranuclear palsy |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| EP2598136A4 (en) | 2010-07-27 | 2015-03-25 | Teva Pharma | DISPERSIONS OF RASAGILINE CITRATE |
| WO2013055689A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | R(+)-n-methyl-propargyl-aminoindan |
| BR112014008555A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-formil-propargil-aminoindano |
| MX2015002062A (es) | 2012-08-17 | 2015-06-05 | Teva Pharma | Formulaciones parenterales de rasagilina. |
| KR20210030632A (ko) | 2019-09-10 | 2021-03-18 | 삼성중공업 주식회사 | Lng 연료탱크 메인티넌스 전용 부유식 해상 구조물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2628432B1 (fr) * | 1988-03-08 | 1990-12-21 | Sanofi Sa | Polymeres d'acide citrique et de diamines, leur procede de preparation et leurs applications notament comme vecteurs de medicaments |
| US5877218A (en) * | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| NZ589445A (en) * | 2008-06-13 | 2013-06-28 | Teva Pharma | Rasagiline for parkinson's disease modification |
| US20100189788A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
-
2012
- 2012-10-09 CN CN201280049740.3A patent/CN103857389A/zh active Pending
- 2012-10-09 EP EP12840538.8A patent/EP2766007A4/en not_active Withdrawn
- 2012-10-09 CA CA2851274A patent/CA2851274A1/en not_active Abandoned
- 2012-10-09 US US13/647,658 patent/US20130089611A1/en not_active Abandoned
- 2012-10-09 EA EA201490756A patent/EA201490756A1/ru unknown
- 2012-10-09 WO PCT/US2012/059353 patent/WO2013055684A1/en active Application Filing
- 2012-10-09 JP JP2014535788A patent/JP2014534195A/ja active Pending
- 2012-10-09 KR KR1020147012453A patent/KR20140074388A/ko not_active Application Discontinuation
- 2012-10-09 AU AU2012323346A patent/AU2012323346A1/en not_active Abandoned
- 2012-10-09 BR BR112014008550A patent/BR112014008550A2/pt not_active IP Right Cessation
- 2012-10-09 MX MX2014004196A patent/MX2014004196A/es unknown
- 2012-10-10 AR ARP120103780 patent/AR088296A1/es unknown
-
2014
- 2014-03-26 IL IL231720A patent/IL231720A0/en unknown
-
2015
- 2015-01-09 HK HK15100232.1A patent/HK1200313A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012323346A1 (en) | 2014-05-15 |
| EA201490756A1 (ru) | 2014-09-30 |
| EP2766007A4 (en) | 2015-03-25 |
| BR112014008550A2 (pt) | 2017-04-18 |
| US20130089611A1 (en) | 2013-04-11 |
| JP2014534195A (ja) | 2014-12-18 |
| WO2013055684A1 (en) | 2013-04-18 |
| MX2014004196A (es) | 2014-05-28 |
| HK1200313A1 (en) | 2015-08-07 |
| KR20140074388A (ko) | 2014-06-17 |
| WO2013055684A8 (en) | 2014-04-10 |
| EP2766007A1 (en) | 2014-08-20 |
| CN103857389A (zh) | 2014-06-11 |
| IL231720A0 (en) | 2014-05-28 |
| CA2851274A1 (en) | 2013-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088296A1 (es) | Citramida de rasagilina, proceso de preparación y composicion farmaceutica | |
| JP2011126894A5 (es) | ||
| AR076974A1 (es) | Metodo para sintetizar pirfenidona | |
| HRP20220455T1 (hr) | Modificirane aminokiseline koje sadrže azid grupu | |
| AR081060A1 (es) | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida | |
| EA201790810A1 (ru) | Активная композиция для мягчителя ткани | |
| ECSP12012155A (es) | Hidrato del hidrocloruro de agomelatina y | |
| CO6700138A1 (es) | Procedimiento de preparación de sal de l-arginina de perindoprilo | |
| AR057067A1 (es) | Procedimiento para preparar sales de tiotropio, sales de tiotropio como tales y composiciones farmaceuticas de las mismas | |
| AR107494A1 (es) | Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y azd9291 anilina o una sal de la misma | |
| BR112017018580A2 (pt) | p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal | |
| ES2571043T3 (es) | Preparación de dihidropiridinas | |
| AR094652A1 (es) | Preparación de sulfonamidas nematocidas | |
| AR106195A1 (es) | Proceso para la preparación de ácido 1-(4-metanosulfonil-2-trifluorometil-bencil)-2-metil-1h-pirrolo[2,3-b]piridin-3-il-acético e intermediarios de dicha síntesis | |
| RU2016103146A (ru) | Способ получения 3-гептанола из смеси, содержащей 2-этилгексаналь и 3-гептилформиат | |
| CU20120136A7 (es) | Hidrato del hidrobromuro de agomelatina y preparación de éste | |
| FR2981068B1 (fr) | Procede de preparation de derives du glycerol, utilisation et composition comprenant lesdits derives du glycerol | |
| AR081025A1 (es) | Procedimiento para preparar acidos dicarboxilicos | |
| BR112015021733A2 (pt) | composto, composição agrícola e método para o tratamento do material vegetal | |
| ES2616133T1 (es) | Composición de unión para calcomanías | |
| PE20230183A1 (es) | Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina | |
| TH123997B (th) | วิธีสำหรับการผลิตองค์ประกอบวีซิเคิล | |
| PL410423A1 (pl) | 4-chloro-2-metylofenoksyoctany alkoksymetylobis(2-hydroksyetylo)metyloamoniowe, sposób otrzymywania i zastosowanie jako środków ochrony roślin | |
| RU2561922C1 (ru) | Пластификатор поливинилхлорида | |
| AR092983A1 (es) | Procedimiento de sintesis del 3-(2-bromo-4,5-dimetoxifenil)propanonitrilo, y aplicacion a la sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |